Literature DB >> 22561842

Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0.

Mieke Van Hemelrijck1, Annette Wigertz, Fredrik Sandin, Hans Garmo, Karin Hellström, Per Fransson, Anders Widmark, Mats Lambe, Jan Adolfsson, Eberhard Varenhorst, Jan-Erik Johansson, Pär Stattin.   

Abstract

In 1987, the first Regional Prostate Cancer Register was set up in the South-East health-care region of Sweden. Other health-care regions joined and since 1998 virtually all prostate cancer (PCa) cases are registered in the National Prostate Cancer Register (NPCR) of Sweden to provide data for quality assurance, bench marking and clinical research. NPCR includes data on tumour stage, Gleason score, serum level of prostate-specific antigen (PSA) and primary treatment. In 2008, the NPCR was linked to a number of other population-based registers by use of the personal identity number. This database named Prostate Cancer data Base Sweden (PCBaSe) has now been extended with more cases, longer follow-up and a selection of two control series of men free of PCa at the time of sampling, as well as information on brothers of men diagnosed with PCa, resulting in PCBaSe 2.0. This extension allows for studies with case-control, cohort or longitudinal case-only design on aetiological factors, pharmaceutical prescriptions and assessment of long-term outcomes. The NPCR covers >96% of all incident PCa cases registered by the Swedish Cancer Register, which has an underreporting of <3.7%. The NPCR is used to assess trends in incidence, treatment and outcome of men with PCa. Since the national registers linked to PCBaSe are complete, studies from PCBaSe 2.0 are truly population based.

Entities:  

Mesh:

Year:  2012        PMID: 22561842     DOI: 10.1093/ije/dys068

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  74 in total

1.  A cautionary note about estimating effects of secondary exposures in cohort studies.

Authors:  K A Ahrens; S R Cole; D Westreich; R W Platt; E F Schisterman
Journal:  Am J Epidemiol       Date:  2015-01-14       Impact factor: 4.897

2.  Physical activity and body mass index as predictors of prostate cancer risk.

Authors:  Alessandra Grotta; Matteo Bottai; Hans-Olov Adami; Swann Arp Adams; Olof Akre; Steven Noel Blair; Daniela Mariosa; Olof Nyrén; Weimin Ye; Pär Stattin; Rino Bellocco; Ylva Trolle Lagerros
Journal:  World J Urol       Date:  2015-01-04       Impact factor: 4.226

3.  A Walking Intervention Among Men With Prostate Cancer: A Pilot Study.

Authors:  Claire H Pernar; Katja Fall; Jennifer R Rider; Sarah C Markt; Hans-Olov Adami; Sven-Olof Andersson; Unnur Valdimarsdottir; Ove Andrén; Lorelei A Mucci
Journal:  Clin Genitourin Cancer       Date:  2017-05-31       Impact factor: 2.872

4.  Snus use, smoking and survival among prostate cancer patients.

Authors:  Kathryn M Wilson; Sarah C Markt; Fang Fang; Caroline Nordenvall; Jennifer R Rider; Weimin Ye; Hans-Olov Adami; Pär Stattin; Olof Nyrén; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2016-12-15       Impact factor: 7.396

5.  Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

Authors:  Daniel D Sjoberg; Andrew J Vickers; Melissa Assel; Anders Dahlin; Bing Ying Poon; David Ulmert; Hans Lilja
Journal:  Eur Urol       Date:  2018-03-05       Impact factor: 20.096

6.  A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.

Authors:  Marco P Licciardello; Anna Ringler; Patrick Markt; Freya Klepsch; Charles-Hugues Lardeau; Sara Sdelci; Erika Schirghuber; André C Müller; Michael Caldera; Anja Wagner; Rebecca Herzog; Thomas Penz; Michael Schuster; Bernd Boidol; Gerhard Dürnberger; Yasin Folkvaljon; Pär Stattin; Vladimir Ivanov; Jacques Colinge; Christoph Bock; Klaus Kratochwill; Jörg Menche; Keiryn L Bennett; Stefan Kubicek
Journal:  Nat Chem Biol       Date:  2017-05-22       Impact factor: 15.040

7.  Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.

Authors:  Weiqiang Li; Mridu Middha; Mesude Bicak; Daniel D Sjoberg; Emily Vertosick; Anders Dahlin; Christel Häggström; Göran Hallmans; Ann-Charlotte Rönn; Pär Stattin; Olle Melander; David Ulmert; Hans Lilja; Robert J Klein
Journal:  Eur Urol       Date:  2018-07-07       Impact factor: 20.096

8.  Five-year nationwide follow-up study of active surveillance for prostate cancer.

Authors:  Stacy Loeb; Yasin Folkvaljon; Danil V Makarov; Ola Bratt; Anna Bill-Axelson; Pär Stattin
Journal:  Eur Urol       Date:  2014-06-30       Impact factor: 20.096

9.  Phosphodiesterase Type 5 Inhibitor Use and Disease Recurrence After Prostate Cancer Treatment.

Authors:  Stacy Loeb; Yasin Folkvaljon; David Robinson; Thorsten Schlomm; Hans Garmo; Pär Stattin
Journal:  Eur Urol       Date:  2015-12-29       Impact factor: 20.096

10.  Immediate versus delayed prostatectomy: Nationwide population-based study (.).

Authors:  Stacy Loeb; Yasin Folkvaljon; David Robinson; Danil V Makarov; Ola Bratt; Hans Garmo; Pär Stattin
Journal:  Scand J Urol       Date:  2016-04-12       Impact factor: 1.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.